Zoster‑Associated Vision Loss

What is Zoster‑Associated Vision Loss?

Zoster‑associated vision loss refers to visual impairment that occurs as a complication of herpes zoster ophthalmicus (HZO), the involvement of the eye and its surrounding structures by the reactivation of the varicella‑zoster virus (VZV). After a person recovers from chickenpox, VZV remains dormant in cranial nerve ganglia. When immunity wanes, the virus can reactivate, travel along the ophthalmic branch of the trigeminal nerve (V1), and damage ocular tissues. The resulting inflammation, scarring, or vascular changes can lead to temporary or permanent loss of vision.

Vision loss may affect one or both eyes and can manifest as blurred vision, reduced visual acuity, blind spots, or even complete blindness, depending on the structures involved (cornea, retina, optic nerve, or blood vessels). Prompt recognition and treatment are essential to preserve sight.

Sources: Mayo Clinic; CDC; National Eye Institute (NEI)​¹

Common Causes

While the primary trigger is varicella‑zoster reactivation, several specific ocular conditions can develop and cause vision loss in the setting of HZO:

• Keratitis – inflammation of the cornea that can lead to ulceration and scarring.
• Uveitis (anterior, intermediate, or posterior) – inflammation of the uveal tract; posterior uveitis can affect the retina and optic nerve.
• Acute retinal necrosis (ARN) – rapidly progressive necrotizing retinitis that threatens the peripheral retina.
• Optic neuritis – inflammation of the optic nerve causing central vision loss.
• Ischemic optic neuropathy – reduced blood flow to the optic nerve secondary to vasculitis.
• Scleritis – painful inflammation of the sclera that can extend to adjacent structures.
• Episcleritis – milder inflammation that may precede more severe disease.
• Glaucoma (neovascular or angle‑closure) – elevated intra‑ocular pressure from vascular changes.
• Conjunctival and eyelid vesicles – while not directly causing vision loss, they signal active viral spread.
• Secondary bacterial infection – can exacerbate corneal ulcers and lead to perforation.

These conditions often coexist; for example, a patient may present with keratitis and anterior uveitis simultaneously.

Associated Symptoms

Patients with zoster‑associated vision loss frequently report additional signs that help clinicians identify HZO:

• Prodromal pain, burning, or tingling in the forehead, scalp, or eye region.
• Clustered vesicular rash following the V1 dermatome (forehead, upper eyelid, tip of the nose – Hutchinson’s sign).
• Redness of the eye (conjunctival injection).
• Photophobia (sensitivity to light).
• Foreign‑body sensation or gritty feeling.
• Tearing or discharge.
• Swelling of the eyelids (blepharitis) or eyelid drooping (ptosis).
• Headache, especially around the temples.
• Systemic symptoms such as fever, malaise, or fatigue, more common in immunocompromised patients.

When to See a Doctor

Vision changes after a shingles rash on the face should never be ignored. Seek medical care promptly if you notice any of the following:

• Sudden or gradual decrease in visual acuity in one or both eyes.
• New onset of double vision (diplopia).
• Persistent eye pain that does not improve with over‑the‑counter analgesics.
• Redness or swelling that spreads beyond the eyelid.
• Development of a rash on the tip of the nose (Hutchinson’s sign) – a strong predictor of ocular involvement.
• Flashing lights, new floaters, or a curtain‑like shadow over part of the visual field (possible retinal detachment).
• Any loss of color perception or inability to see contrast.

Early ophthalmology referral is crucial; treatment begun within 72 hours of symptom onset markedly improves visual outcomes.

Diagnosis

Evaluation combines a detailed history, focused eye examination, and targeted investigations.

Clinical Examination

• Visual acuity testing – baseline measurement of how well the patient sees.
• External inspection – assess rash distribution, eyelid edema, and corneal opacity.
• Slit‑lamp biomicroscopy – visualizes cornea, anterior chamber, and iris for keratitis, uveitis, or endothelial damage.
• Fundus examination (indirect ophthalmoscopy) – evaluates retina, optic nerve, and vasculature for necrosis, hemorrhages, or vasculitis.
• Intra‑ocular pressure (IOP) measurement – screens for glaucoma.

Laboratory & Imaging Studies

• Polymerase chain reaction (PCR) of tear or aqueous humor samples – confirms VZV DNA, especially in atypical cases.
• Serologic testing – anti‑VZV IgM/IgG can support a recent reactivation.
• Optical coherence tomography (OCT) – high‑resolution cross‑section of retina and optic nerve to detect edema or thinning.
• Fluorescein angiography – highlights retinal or choroidal vascular leakage.
• Magnetic resonance imaging (MRI) of the orbits – useful when optic nerve inflammation or cavernous sinus involvement is suspected.

Treatment Options

Management is multimodal, targeting the virus, reducing inflammation, and protecting ocular structures.

Antiviral Therapy

• Acyclovir 800 mg orally five times daily for 7–10 days.
• Valacyclovir 1 g orally three times daily (preferred for better bioavailability).
• Famciclovir 500 mg orally three times daily.
• Intravenous acyclovir (10 mg/kg every 8 hours) is indicated for severe ocular disease, immunocompromised patients, or if oral therapy cannot be tolerated.

Start antivirals within 72 hours of rash onset; treatment may still be beneficial later if vision is threatened.

Corticosteroids

• Topical prednisolone acetate 1% drops every 1–2 hours (tapered over weeks) for anterior uveitis or keratitis.
• Periocular or intravitreal steroid injections for posterior segment inflammation, guided by ophthalmology.
• Systemic prednisone (0.5–1 mg/kg) may be added in cases of optic neuritis or extensive vasculitis, but always after antiviral coverage is established.

Adjunctive Therapies

• Lubricating eye drops (preservative‑free artificial tears) to relieve epithelial dryness.
• Cycloplegic agents (e.g., cyclopentolate) to reduce ciliary spasm and pain.
• Topical antibiotics if secondary bacterial infection is suspected.
• IOP‑lowering medications** (beta‑blockers, prostaglandin analogues) for glaucoma.
• Vitrectomy in cases of retinal detachment or non‑resolving vitreous haze.